You are reporting the following post to the moderators for review and possible removal from the forum
RE: Deriba Merga - How Does He Do It? Who Else Has Had Done This?
d) EPO biogenerics in non-regulated markets
As erythropoietin is a rather high price product, many countries with healthcare systems which cannot afford to pay Western prices, approved erythropoietin products originating from manufacturers which do not respect patent protection. Such biogeneric erythropoietin products primarily come from companies with a home base in South America, India, Korea and China. These products mainly serve to satisfy the EPO needs of emerging countries, but especially Indian companies are working to qualify the manufacturing of biogeneric EPO to meet European or FDA standards. As the local low price markets are rather small, these companies are aiming at Western markets in their long term business strategy.
e) Next generation Erythropoiesis Stimulating Agents (ESA)
The large EPO market is not only “attacked” by biogeneric EPO, but also by next generation erythropoiesis stimulating agents (ESA), among them also molecules which can be orally administered. The most advanced development of an oral ESA are a group of compounds originating from Fibrogen, now in co-development with Astellas for certain territories, now including Europe .
Hit the submit button below if you want us to review the post.